The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
US pharma major AbbVie has announced an exclusive worldwide license option agreement with clinical-stage biotech Cugene for CUG252, a potential best-in-class Treg-selective interleukin (IL)-2 mutein, as well as other novel IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases. 17 May 2022
Today, abemaciclib becomes the first successful addition in England to adjuvant endocrine therapy for early breast cancer patients in nearly two decades, following the Medicines and Healthcare products Regulatory Agency (MHRA) approval. 17 May 2022
US biotech major Gilead Sciences yesterday announced the US Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP). 17 May 2022
Industry commentator GlobalData has presented an analysis outlining what it describes as an explosion of research in immuno-neurology over the last decade. 17 May 2022
USA-based clinical-stage biotech Elicio Therapeutics has entered into a clinical supply agreement with Regeneron Pharmaceuticals to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo (cemiplimab). 17 May 2022
Building on a licensing deal with AstraZeneca, British biotech RQ Biotechnolgoy has announced its launch, with a focus on developing antibody treatments and preventive therapies. 17 May 2022
Privately-held Icelandic biosimilars developer Alvotech Holdings has announced positive top-line results from a pharmacokinetic (PK) study for AVT04, its proposed biosimilar to Stelara (ustekinumab). 17 May 2022
Alzheimer’s disease (AD) is a progressive fatal neurological disorder and the most common cause of dementia primarily affecting the elderly population, with AD-associated dementia accounting for two-thirds of dementia cases in Japan. 17 May 2022
UK pharma major GlaxoSmithKline has presented data suggesting favorable long-term efficacy with single inhaler triple therapy (SITT) Trelegy (fluticasone furoate/ umeclidinium/vilanterol) Ellipta, compared to alternative triple therapies. 16 May 2022
Swiss pharma giant Roche has not been the only company to suffer in the stock market as a result of the failure of its Phase III trial in lung cancer that was announced last week. 16 May 2022
The Serum Institute of India (SII) has sought the government’s approval to manufacture its indigenously developed quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, after the completion of Phase II/III clinical trials in order to ensure its early availability in the country. 16 May 2022
Shares of Travere Therapeutics were up 13% at $25.08 in early trading today, as it revealed that the US Food and Drug Administration has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN). 16 May 2022
Full results from the MANDALA Phase III trial have been published by British firms Avillion and AstraZeneca in the New England Journal of Medicine. 16 May 2022
Anglo-Austrian firm F2G Ltd has entered a strategic collaboration with Japan’s Shionogi to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in Europe and Asia. 16 May 2022
Japanese drugmaker Takeda has announced the Indian launch of Adynovate, an extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology (controlled PEGylation), for hemophilia A patients. 16 May 2022
Japanese drugmaker Otsuka says it has decided to terminate its global license agreements with Akebia Therapeutics for vadadustat, under development as an oral treatment for anemia associated with chronic kidney disease (renal anemia). 16 May 2022
A Phase III trial of Sarclisa (isatuximab), a CD38-targeting antibody used to treat multiple myeloma, has produced impressive progression free survival results. 16 May 2022
Proteros biostructures, a privately held German company with expertise in structure-based drug discovery, today announced an expansion of its collaboration with AstraZeneca focused on the discovery and development of novel epigenetic drugs. 16 May 2022